Trials / Unknown
UnknownNCT04646902
Kynurenine/Tryptophan Ratio in Hypertension Associated to Obstructive Sleep Apnea
Relevance of the Ratio Kynurenine/Tryptophan to Characterize Hypertension Associated to Obstructive Sleep Apnea (KYNTOSA)
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 203 (actual)
- Sponsor
- Universidade Nova de Lisboa · Academic / Other
- Sex
- All
- Age
- 30 Years
- Healthy volunteers
- Accepted
Summary
Obstructive Sleep Apnea (OSA) is an independent risk factor for hypertension (HTN) and the most common cause of resistant HTN. The mechanisms underlying OSA-associated HTN are not completely understood. This is crucial to find novel therapeutic targets of OSA-associated HTN. The Aryl Hydrocarbon Receptor (AHR) is a cytosolic transcription factor that has been linked with the pathogenesis of HTN. This study aims to evaluate the role of endogenous ligands of AHR such as kynurenine in discriminating patients with OSA-associated HTN. For that aim, a case-control study will be performed in patients with and without hypertension exposed and not exposed to OSA. Kynurenine and other metabolites will be quantified in urine and serum samples.
Conditions
Timeline
- Start date
- 2021-03-25
- Primary completion
- 2023-09-01
- Completion
- 2024-03-01
- First posted
- 2020-11-30
- Last updated
- 2023-12-07
Locations
5 sites across 1 country: Portugal
Source: ClinicalTrials.gov record NCT04646902. Inclusion in this directory is not an endorsement.